Angelo Maiolino
Rio De Janeiro, RJ, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma.
Journal: British journal of haematology
Published: May 19, 2026
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS.
Journal: Leukemia
Published: February 19, 2026
Real-world outcomes of CD34⁺ mobilization and early autologous hematopoietic stem cell transplantation recovery after daratumumab-based induction.
Journal: Hematology, transfusion and cell therapy
Published: February 11, 2026
Contribution of cone-beam computed tomography to the evaluation of lesions resulting from multiple myeloma and to the early diagnosis of the disease: A scoping review.
Journal: Imaging science in dentistry
Published: December 02, 2025
Emerging Real-World Treatment Patterns and Clinical Outcomes of Multiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Study in the Private Healthcare Sector.
Journal: Current oncology (Toronto, Ont.)
Published: October 20, 2025
A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant.
Journal: Future oncology (London, England)
Published: October 08, 2025
Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.
Journal: Blood cancer journal
Published: May 28, 2025
The potential role of biosimilars in healthcare sustainability in Latin America.
Journal: Expert opinion on biological therapy
Published: May 15, 2025
Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma: Latin American Expert Panel Recommendations.
Journal: Oncology and therapy
Published: April 24, 2025
Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Journal: Nature medicine
Published: February 13, 2025
Last Updated: 09/26/2026